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Abstract
Background Transcatheter aortic valve implantation
(TAVI) has recently developed into an acceptable alter-
native to conventional surgery in high-risk patients. How-
ever, information on the identiﬁcation of patients gaining
most beneﬁt from this procedure is still limited. The aim of
this study was to evaluate safety and efﬁcacy of TAVI in
different patient cohorts.
Methods Between August 2008 and December 2010, 180
high-risk patients underwent TAVI at our institution (97
transapical and 83 transfemoral approaches). Periproce-
dural complications as well as mortality and incidence of
MACCE during follow-up were recorded.
Results Mean age was 82 ± 5 years, and mean logistic
EuroScore 27 ± 14%. In the total cohort, 30-day mortality
was 8.9% and 12-month survival (according to Kaplan–
Meier-analysis) 72%, with no signiﬁcant differences
between the two approaches. However, a signiﬁcant
difference in survival was obvious after stratiﬁcation of
patients according to logistic EuroScore mortality esti-
mates. Survival proportions at 1 year were 62% in patients
with logistic EuroScore[40%, 71% in patients with Euro-
Score 20–40% and 80% in octogenarians with EuroScore
\20% (P = 0.009). Furthermore, the observed median
event-free survival as an indicator for morbidity ranged
between 315 days in the ﬁrst, 442 days in the second and
710 days in the third group (P = 0.1).
Conclusions TAVI proved to be feasible with reproduc-
ible results. However, mortality and rehospitalization rates
were considerably high in speciﬁc patient cohorts, sug-
gesting that the risk-to-beneﬁt ratio of TAVI should be
validated individually. In the present study, octogenarians
with logistic EuroScore\20% could be identiﬁed as can-
didates apparently gaining high beneﬁt from the procedure.
Keywords Aortic valve  Aortic stenosis 
Transcatheter aortic valve implantation  TAVI
Introduction
Degenerative aortic stenosis (AS) has become the most
frequent type of valvular heart disease in Europe and North
America, and disease prevalence is still increasing due to
the ageing population. Early valve replacement is strongly
recommended in all symptomatic patients with severe AS
[1]. However, open-heart surgery is considered to high risk
in more than 30% of elderly patients who therefore remain
untreated [2]. To address this problem, transcatheter aortic
valve implantation (TAVI) was introduced initially for non-
operable patients by Cribier in 2002, and has blossomed out
to an alternative to conventional surgery in high-risk oper-
able patients since then [3]. Nevertheless, information on
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limited complicating the identiﬁcation of patients gaining
most beneﬁt from this procedure.
Methods
Study design
The present analysis includes the ﬁrst 180 consecutive
patients undergoing TAVI at our institution between August
2008 and December 2010. The aim of this retrospective
study completely independent from industry was to assess
safety, efﬁcacy and beneﬁt of the procedure. Figure 1 dem-
onstrates the study design. Clinical examination, echocar-
diography and analysis of blood samples were performed on
admission. At discharge, periprocedural complications and
in-hospital mortality were evaluated and echocardiography
was repeated. All 180 patients were followed by telephone
contact over a ﬁxed period of 2 weeks in 2011 using a
standardized questionnaire to inquire clinical symptoms,
further hospitalizations and cases of death. Following the
patients’ or their relatives’ statements, general practitioners,
cardiologistsandotherhospitalswerecontactedandmedical
documents were acquired to investigate the incidence of
major adverse cardiovascular and cerebrovascular events
(MACCE) and the causes of death during follow-up.
The study was approved by the local ethics committee,
and written informed consent was obtained from all
patients.
Patient screening and eligibility
The decision to treat a patient by TAVI was made by a
‘‘heart team’’ consisting of an interventional cardiologist
and a cardiac surgeon as suggested by common recom-
mendations [4, 5]. Presence of severe AS was conﬁrmed
via echocardiography according to the American College
of Cardiology/American Heart Association’s (ACC/AHA)
valve guidelines (aortic jet velocity[4 m/s, mean gradient
[40 mmHg, AVA \1.0 cm
2). TAVI was only proposed
in patients with severe AS at high risk for surgery who
presented with severe symptoms (New York Heart Asso-
ciation, NYHA functional class C2). According to rec-
ommendations of the European Society of Cardiology
(ESC) [4], the decision whether a patient was at high risk
for surgery was made by clinical judgement in combination
with the assessment of the logistic EuroScore.
Devices and procedure
All procedures were performed by a combined team
including an interventional cardiologist, a cardiac surgeon,
a cardio-anaesthesiologist and an imaging specialist.
Implantation procedures using the retrograde transfemoral
(TF) and the antegrade transapical (TA) approach were
performed as previously described [4, 6–8].
Both prostheses currently available for TAVI in
Germany are used in our department. One device is the
balloon-expandable Edwards Sapien valve (Edwards Life-
sciences Inc., Irvine, CA, USA) available in 23 and 26 mm
sizes at that time. Until May 2010, the Retroﬂex 3 delivery
catheter (requiring 22 or 24F introducers) was used in
transfemoral procedures, and arterial access as well as
closure of the access site was performed surgically neces-
sitating general anaesthesia during implantation. After-
wards, the introduction of the Novaﬂex delivery catheter
enabled the use of smaller introducers (18/19F) and con-
secutively the performance of a pure percutaneous proce-
dure in conscious sedation (closure of the access site by
Prostar XL, Abbott Vascular, Chicago, IL, USA).
The second device is the self-expanding CoreValve
Revalving System (Medtronic, Minneapolis, MN, USA). It
was available in 26 and 29 mm sizes at that time ﬁtting
N=180 patients accepted for TAVI
N=97 transapical
approaches
N=83 transfemoral
approaches
Pre-procedural evaluation on admission (N=180) 
Clinical examination, echocardiography, blood samples
Evaluation at discharge (N=180)
In-hospital mortality, periprocedural complications, 
echocardiography
Telephone follow-up over a fixed period of 2 weeks
in 2011 (N=179) 
- Mortality and incidence of MACCE during follow-up
- Clinical symptoms at time of contact
TAVI-procedures (N=180)
Between August 2008 and December 2010
Fig. 1 Study design
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123through an 18F introducer. Therefore, CoreValve implan-
tation was performed completely percutaneously.
Treatment strategy
Procedural approach and type of device were chosen by the
‘‘heart team’’ to offer the best treatment option to each
individual patient. In principle, the transfemoral approach
was selected in the absence of signiﬁcant peripheral artery
disease. Furthermore, we principally favoured the Edwards
Sapien device due to the previously described lower inci-
dence of postprocedural new pacemaker implantations.
However, the CoreValve prosthesis was offered to patients
whose aortic annulus was [25 mm or who were at high
risk for general anaesthesia due to speciﬁc comorbidities.
Since the introduction of the Novaﬂex catheter for trans-
femoral Edwards Sapien implantations allowed the per-
formance of these procedures under conscious sedation, the
number of implanted CoreValves decreased.
Study endpoints
Recently, a consensus report from the Valve Academic
Research Consortium (VARC) proposed standardized
endpoint deﬁnitions to enable comparison between TAVI
trials [9]. VARC deﬁnitions which are in detail described in
the consensus report were adopted for the present study.
Safety endpoints contained the occurrence of periproce-
dural myocardial infarction, TIA, stroke, bleeding compli-
cations, acute kidney injury (AKI), vascular and access-site
complications, and prosthetic valve-associated complica-
tions (conduction disturbances, coronary obstruction, valve
thrombosis, endocarditis). In addition, therapy-speciﬁc
endpoints like unplanned use of cardiopulmonary bypass,
conversion to surgical AVR, ventricular perforation,
placement of a second transcatheter valve into the primary
transcatheter valve (valve-in-valve), and re-intervention
after the index procedure were recorded.
Concerning follow-up, all-cause mortality was deﬁned
as the primary clinical endpoint according to VARC pro-
posals. Survival proportions were reported at 30 days,
6 months and 1 year. Furthermore, the occurrence of
MACCE comprising a composite of death of any reason
and hospitalization due to congestive heart failure, myo-
cardial infarction, stroke, and aortic valve-related events
(prosthesis dysfunction, re-intervention, endocarditis,
thrombosis) was chosen as clinical beneﬁt endpoint.
Statistical analysis
For continuous variables, the Kolmogorov–Smirnov nor-
mality test was performed. Continuous variables are pre-
sented as mean ± SD or as median and interquartile range
(in the absence of normality distribution) and were com-
pared between groups using the unpaired t test or the
Mann–Whitney test, respectively. Categorical variables are
presented as absolute numbers and percentage and were
compared by Pearson’s Chi-square test. A value of
P\0.05 was considered statistically signiﬁcant. Survival
analysis was performed by the Kaplan–Meier method, with
patients censored as of the last date known alive. Survival
proportions at 6 and 12 months were also calculated
according to Kaplan–Meier-analysis. Statistical analyses
were performed with graph pad prism version 4.0 and
MedCalc version12.0.4.0.
Results
Baseline characteristics
TAVI was performed in 180 symptomatic patients (base-
line characteristics demonstrated in Table 1). The total
cohort was characterized by a mean age of 82 ± 5 years
and a high risk for conventional surgery estimated by a
mean logistic EuroScore of 27 ± 14%. In 65% of patients,
the logistic EuroScore exceeded 20%. The indications for
TAVI in the remaining cases were porcelain aorta, end-
stage pulmonary disease, reduced life expectancy due to
malignoma, and refusal of conventional surgery because of
very high age ([80 years).
The transapical approach was chosen in 97 cases,
whereas the other 83 patients were treated transfemorally.
Comparing TA and TF patients, the only statistically sig-
niﬁcant differences were the higher incidences of periph-
eral vascular disease (38 vs. 23%, P = 0.03) and chronic
lung disease (40 vs. 28%, P = 0.008) in the TA group.
Importantly, the logistic EuroScore did not differ signiﬁ-
cantly (28 ± 15% in the TA cohort vs. 26 ± 13% in the
TF cohort, P = 0.3).
Procedural parameters, periprocedural complications
and in-hospital mortality
Procedural characteristics and incidence of speciﬁc com-
plications are demonstrated in Tables 2 and 3. Transapical
procedures were always performed under general anaes-
thesia, transfemoral cases in 37% under sedation and
analgesia, resulting in a signiﬁcantly lower median venti-
lation time in the TF cohort (2.8 vs. 3.6 h, P\0.0001).
Total procedure time, ﬂuoroscopy time, and volumes of
contrast medium were signiﬁcantly higher in transfemoral
procedures, whereas the time from procedure to discharge
did not differ signiﬁcantly between both approaches.
The TAVI procedure was terminated successfully in 174
cases (96.7%). Four patients died periprocedurally (1 aortic
Clin Res Cardiol (2012) 101:553–563 555
123dissection, 3 cardiogenic shocks), in one case the apex
anatomy proved unsuitable for apical puncture, and during
one procedure the implantation of a second device (‘‘valve-
in-valve’’) became necessary (details are published in
[10]). No conversion to surgical aortic valve replacement
was carried out. In ﬁve patients, an unplanned use of
cardiopulmonary bypass was necessary to manage hemo-
dynamic compromise. Postprocedural myocardial infarc-
tion occurred in three persons (1.7%). Nine patients (5%)
experienced major strokes with subsequent death in ﬁve
cases (3 TA and 2 TF patients) contributing substantially to
in-hospital mortality. Of note, the incidence of major
Table 1 Baseline characteristics
Combined (n = 180) Transapical (n = 97) Transfemoral (n = 83) P
Age (years) 82.1 ± 5.4 81.7 ± 5.8 82.6 ± 4.9 0.3
Sex (male) 54 (30%) 27 (28%) 27 (33%) 0.5
BMI (kg/m
2) 26.4 ± 4.8 26.6 ± 5.3 26.2 ± 5.3 0.65
Comorbidities
EF\35% 26 (14%) 12 (12%) 14 (17%) 0.4
Coronary artery disease 120 (67%) 64 (66%) 56 (68%) 0.8
Prior PCI 50 (28%) 26 (27%) 24 (29%) 0.8
Prior CABG 27 (15%) 18 (19%) 9 (11%) 0.09
Prior other thoracotomy 6 (3%) 2 (2%) 4 (5%) 0.3
Porcelain aorta 4 (2%) 3 (3%) 1 (1%) 0.4
Previous aortic bioprosthesis 4 (2%) 2 (2%) 2 (2%) 0.9
Peripheral vascular disease 56 (31%) 37 (38%) 19 (23%) 0.03*
Prior cerebral ischaemic event 21 (12%) 12 (12%) 9 (11%) 0.8
Chronic pulmonary disease 57 (32%) 39 (40%) 18 (28%) 0.008*
Diabetes 64 (36%) 32 (33%) 32 (39%) 0.4
GFR\60 mL/min 110 (61%) 61 (63%) 49 (59%) 0.6
GFR\30 mL/min 30 (17%) 20 (21%) 10 (12%) 0.12
Calculated surgical risk (Logistic EuroScore) (%) 26.8 ± 14.0 27.9 ± 14.9 25.6 ± 13.0 0.3
Clinical characteristics
NYHA class III 131 (73%) 71 (73%) 60 (72%) 0.9
NYHA class IV 38 (21%) 21 (22%) 17 (21%) 0.8
Oedema 85 (47%) 46 (47%) 39 (47%) 1.0
Effusions 35 (19%) 24 (25%) 11 (13%) 0.05
Moist rales 64 (36%) 37 (38%) 27 (33%) 0.4
Syncope 46 (26%) 22 (23%) 24 (29%) 0.4
Categorical variables are presented as absolute number and percentage (in parentheses), continuous variables as mean ± SD. For comparison
between TA and TF patients, the unpaired t test was used for continuous and the Chi-square test for categorical variables
Table 2 Procedural characteristics
Combined (n = 180) Transapical (n = 97) Transfemoral (n = 83) P
Total procedure time (min) 90.1 ± 45.7 78.4 ± 38.3 104.1 ± 49.9 0.0002*
Fluoroscopy time (min) 12.1 ± 9.4 7.0 ± 4.3 16.1 ± 10.3 \0.0001*
Volume of contrast medium (mL) 116.1 ± 71.1 85.4 ± 30.7 152.3 ± 87.2 \0.0001*
Procedure to discharge (days) 13.9 ± 10.7 13.2 ± 8.9 14.8 ± 12.5 0.31
Type of valve
Edwards Sapien (n) 156 97 59 –
Medtronic CoreValve (n)2 4 N A 2 4 –
General anaesthesia [n (%)] 149 (82.8%) 97 (100%) 52 (62.7%) \0.0001*
Conscious sedation [n (%)] 31 (17.2%) 0 31 (37.3%) \0.0001*
Categorical variables are presented as absolute number and percentage (in parentheses), continuous variables as mean ± SD. For comparison
between TA and TF patients, the unpaired t test was used for continuous and the Chi-square test for categorical variables
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123Table 3 Perioperative outcome
Combined (n = 180) Transapical (n = 97) Transfemoral (n = 83) P
Procedure-related complications
Successful termination of procedure 174 (96.7%) 93 (95.6%) 81 (97.6%) 0.5
Conversion to surgical AVR 0 0 0 1.0
Unplanned use of cardiopulmonary bypass 5 (2.8%) 4 (4.1%) 1 (1.2%) 0.2
Ventricular perforation 1 (0.6%) 0 1 (1.2%) 0.3
‘‘Valve-in-valve’’ 1 (0.6%) 1 (1.0%) 0 0.4
Coronary obstruction 2 (1.1%) 1 (1.0%) 1 (1.2%) 0.9
Re-intervention 2 (1.1%) 0 2 (2.4%) 0.1
Percutaneous 2 (1.1%) 0 2 (2.4%) 0.1
Surgical 0 0 0 –
Myocardial infarction
a 3 (1.7%) 3 (3.1%) 0 0.1
Stroke
a 9 (5.0%) 4 (4.1%) 5 (6.0%) 0.6
TIA
a 2 (1.1%) 2 (2.1%) 0 0.1
Peri-interventional death (\24 h) 4 (2.2%) 2 (2.1%) 2 (2.4%) 0.9
30-day-mortality 16 (8.9%) 12 (12.4%) 4 (4.8%) 0.08
In-hospital-mortality 18 (10.0%) 12 (12.4%) 6 (7.2%) 0.25
Bleeding complications combined 94 (52.2%) 44 (45.4%) 50 (60.2%) 0.046*
Life-threatening or disabling bleeding
a 21 (11.7%) 8 (8.2%) 13 (15.7%) 0.1
Major bleeding
a 10 (5.6%) 3 (3.1%) 7 (8.4%) 0.1
Life-threatening ? major bleeding combined 31 (17.2%) 11 (11.3%) 20 (24.1%) 0.02*
Minor bleeding
a 63 (35.0%) 33 (34.0%) 30 (36.1%) 0.8
Cardiac tamponade 3 (1.7%) 2 (2.1%) 1 (1.2%) 0.7
Patients with RBC transfusions 87 (48.3%) 42 (43.3%) 45 (54.2%) 0.1
Number of units per transfusion 3.1 ± 2.2 2.9 ± 2.0 3.3 ± 2.4 0.5
Drop in Hb following procedure (g/dL) 2.9 ± 1.3 2.9 ± 1.2 2.8 ± 1.4 0.4
Acute kidney injury (modiﬁed RIFLE classiﬁcation
a)
Stage 1 54 (30.0%) 24 (24.7%) 30 (36.1%) 0.1
Stage 2 41 (22.8%) 27 (27.8%) 14 (16.9%) 0.08
Stage 3 29 (16.1%) 24 (24.7%) 5 (6.0%) 0.001*
Patients requiring RRT 25 (13.9%) 21 (21.6%) 4 (4.8%) 0.001*
Patients remaining permanently dependant on RRT 2 (1.1%) 1 (1.0%) 1(1.2%) 0.9
Creatinine before procedure (mg/dL) 1.2 ± 0.6 1.3 ± 0.7 1.2 ± 0.6 0.3
Max. creatinine up to 72 h after procedure (mg/dL) 1.7 ± 1.2 2.0 ± 1.3 1.4 ± 0.7 0.0001*
Access-related complications
a
Major access complications 22 (12.2%) 2 (2.1%) 20 (24.1%) \0.0001*
Unplanned surgical intervention 10 (5.6%) 1 (1.0%) 9 (10.8%) 0.004*
Unplanned percutan. intervention 6 (3.3%) 0 6 (7.2%) 0.007*
Thoracic aortic dissection 1 (0.6%) 0 1 (1.2%) 0.3
Minor access complications 6 (3.3%) 2 (2.1%) 4 (4.8%) 0.3
Prosthetic valve-associated complications
New-onset conduction disturbances
LBBB 12 (6.7%) 0 12 (14.5%) 0.0001*
Third degree atrioventricular block 5 (2.8%) 1 (1.0%) 4 (4.8%) 0.1
New permanent pacemaker 9 (5.0%) 1 (1.0%) 8 (9.6%) 0.008*
Supraventricular arrhythmias 29 (16.1%) 16 (16.5%) 13 (15.7%) 0.9
Valve endocarditis 5 (2.8%) 3 (3.1%) 2 (2.4%) 0.7
Categorical variables are presented as absolute number and percentage (in parentheses), continuous variables as mean ± SD. For comparison between TA
and TF patients, the unpaired t test was used for continuous and the Chi-square test for categorical variables
a Deﬁnitions according to proposed endpoint deﬁnitions from the Valve Academic Research Consortium (VARC) [9]
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123strokes did not differ signiﬁcantly between the TA and the
TF cohort (4 vs. 6%, P = 0.6).
Access-related problems were more common in the TF
group (P\0.0001) with 20 TF patients (24%) experienc-
ing major vascular complications. One of them died con-
sequently (thoracic aortic dissection). However, we also
experienced two patients (2%) with major access-compli-
cations in the TA group (1 primary failure of apex closure,
1 purulent wound infection with indication for surgical
re-intervention); the ﬁrst patient died on day 55.
Bleeding was a common problem following both TAVI
procedures, necessitating red blood cell transfusions in
48% of TAVI-patients (mean, 3.1 ± 2.2 U per transfu-
sion). However, relevant bleeding complications (combi-
nation of life-threatening and major bleeding) occurred
more frequently after transfemoral procedures (24 vs. 11%,
P = 0.02).
Worsening of renal function was observed more often
after transapical procedures despite lower volumes of
contrast medium used. Whereas baseline serum creatinine
levels did not differ signiﬁcantly, the maximum levels up
to 72 h after the procedure were signiﬁcantly higher in the
transapical cohort (2.0 ± 1.3 vs. 1.4 ± 0.7 mg/dl,
P = 0.0001), resulting in a signiﬁcantly higher need for
renal replacement therapy (22 vs. 5%, P = 0.001).
Conduction disturbances were more frequent in the TF
cohort (new-onset LBBB in 14.5 vs. 0%, P\0.0001),
necessitating the implantation of new permanent pace-
makers in 10 vs. 1% (P = 0.008). In transfemoral
approaches, the new onset of a LBBB occurred signiﬁ-
cantly more often with the CoreValve prosthesis (46% CV
vs. 2% Edwards, P\0.0001), whereas the incidence of a
third degree atrioventricular block was more frequent with
the Edwards device (0% CV vs. 7% Edwards, P = 0.2).
The need for new permanent pacemaker implantation was
higher after CoreValve implantation (17% CV vs. 7%
Edwards, P = 0.2), but the difference did not reach sta-
tistical signiﬁcance.
In discordance with the logistic EuroScore mortality
estimate of 27%, the observed 30-day-mortality was 8.9%
(12.4% in the TA cohort vs. 4.8% in the TF group,
P = 0.08) and in-hospital mortality 10.0% (12.4% in the
TA cohort vs. 7.2% in the TF group, P = 0.25). Four
patients (2.2%) died periprocedurally. The other 14
in-hospital deaths were a consequence of stroke (n = 5),
pneumonia (n = 3), cardiogenic shock (n = 2), septic-
cardiogenic shock (n = 1), mesenterical ischaemia (n = 1),
aspiration (n = 1), and unexplained sudden death (n = 1).
Echocardiographic valve performance
At discharge, a signiﬁcant improvement of multiple echo-
cardiographic parameters could be documented. We saw a
reduction in transaortic mean gradient from 43.1 ± 16.9 to
10.6 ± 5.0 mmHg, an increase in mean estimated aortic
valve area from 0.69 ± 0.28 to 1.6 ± 0.5 cm
2,a n
improvement of mean left ventricular ejection fraction
from 49.7 ± 11.8% to 53.7 ± 8.5% and a reduction of
mean estimated pulmonary artery systolic pressure from
47.8 ± 14.7 to 41.5 ± 13.4 mmHg (all P\0.0001). After
TAVI, a mild aortic regurgitation (paravalvular in most
cases) occurred frequently (48%). However, moderate AR
was only observed in 7%, and severe AR was not present.
In a subgroup of 33 patients, transthoracic echocardi-
ography was repeated 12 months postprocedure. The sus-
tained improvement of left ventricular ejection fraction,
increase in aortic valve area, and reduction in transaortic
mean gradient could be conﬁrmed, and no signiﬁcant
structural or hemodynamic device deterioration was
observed (data not shown; extensive analyses of long-term
transcatheter valve durability have previously been pub-
lished [11]).
Mid-term outcome—mortality
The telephone follow-up was 99.4% complete. Survival
proportions at 6 and 12 months were 82 and 72%,
respectively. Between the two approaches, no signiﬁcant
differences could be observed (P = 0.9). Figure 2a illus-
trates the Kaplan–Meier survival after percutaneous valve
implantation in the whole cohort and 2b for both approa-
ches separated.
At a median follow-up of 319 days, 51 of all 180
patients (28.3%) had died. The causes of death (n = 33)
occurring after discharge from the index hospitalization
were the following: unexplained sudden deaths (n = 8);
congestive heart failure (n = 5); device endocarditis
(n = 2); stroke (n = 1); pneumonia or other septicaemia
(n = 4); cancer (n = 1); surgery after hip fracture (n = 1);
ileus of small intestine (n = 1); old age and bad clinical
condition (n = 10). Altogether, 16 deaths (48%) had to be
counted as cardiovascular.
Mid-term outcome—event-free survival
Furthermore, the occurrence of major adverse cardiovas-
cular events during follow-up was explored (see Fig. 3a).
Reasons for further hospitalization were the following (one
patient could have more than one event): congestive heart
failure (n = 26), stroke (n = 9), myocardial infarction
(n = 4), access complications of TAVI procedure occur-
ring after ﬁrst discharge (n = 4), syncope requiring pace-
maker implantation (n = 3), and aortic valve-related
events (2 reinterventions, 5 cases of suspected device
endocarditis). Survival curves (P = 0.8) as well as
observed median event-free survival (424 days in the
558 Clin Res Cardiol (2012) 101:553–563
123transfemoral and 442 days in the transapical group) did not
differ signiﬁcantly between both procedures (see Fig. 3b).
Whereas 94% of patients had presented with dyspnoea
of NYHA functional classes III and IV at baseline, 57%
had no and 29% only mild dyspnoea (NYHA II) at follow-
up. However, 12% still complained of dyspnoea NYHA
class III and 2% of dyspnoea at rest after TAVI (see
Fig. 4).
Discussion
Patient characteristics
Regarding the total cohort, our patient population is com-
parable to that of many other publications concerning age,
comorbidities and logistic EuroScore [3, 11–18]. However,
in contrast to other studies, logistic EuroScore and most
other baseline parameters did not differ signiﬁcantly
between transapical and transfemoral patients. We attribute
this fact to our previously described treatment strategy
allocating a signiﬁcant proportion of higher risk patients to
the transfemoral approach to avoid general anaesthesia.
Early outcome and periprocedural complications
Procedural safety and outcome of TAVI at our institution
are not inferior to that of other documented series [3, 11–
19]. Procedural success was very high (96.7%). The 30-day
mortality (as-treated analyses) of 8.9% was well in line
with the one observed in other series ranging from 5.2 [3]
to 12.4% [18]. However, we could not demonstrate a sig-
niﬁcant difference in 30-day mortality between transapical
and transfemoral procedures (12.4 vs. 4.8%, P = 0.08).
Comparing exclusively Edwards implantations in TA and
TF approaches, no statistical signiﬁcant difference could be
observed either (12.4 vs. 5.1%, P = 0.13). In addition, we
saw no signiﬁcant effect of the learning curve: 30-day
mortality did not differ between the ﬁrst and the second
half of implantations in all procedures combined
(P = 0.6), in transfemoral approaches (P = 1.0) or in
transapical approaches (P = 0.6).
The correlation between postprocedural worsening of
renal function and morbidity as well as mortality is well
documented. We observed a high incidence of stage 3 AKI
(16%), and in 15% renal replacement therapy was required.
Of note, the incidence of both events was signiﬁcantly
higher after transapical procedures (25 vs. 6% and 22 vs.
5%, P = 0.001) in spite of comparable baseline serum
creatinine levels. Regarding exclusively TA patients, per-
sons with AKI stage III had signiﬁcantly lower minimum
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Fig. 2 All-cause mortality Kaplan–Meier survival during follow-up
in a all 180 patients treated with TAVI, b patients after transapical or
transfemoral procedures separated, and c three patient cohorts
stratiﬁed according to preoperative logistic EuroScore mortality
estimates
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123haemoglobin values after TAVI and received signiﬁcantly
more red blood cell transfusions than individuals with
lower AKI stages. For example, in patients without AKI
(n = 22) haemoglobin fell to a minimum of 9.3 ± 1.1 g/dl
and 0.3 ± 0.7 RBC units were administered, whereas in
stage-III AKI patients (n = 24) minimum haemoglobin
was 8.2 ± 1.0 g/dl (P = 0.0004) and 3.0 ± 2.9 RBC units
were given (P\0.0001). These ﬁndings suggest that
severity of AKI in transapical procedures depends on the
extent of post-operative anaemia. A similar signiﬁcant
correlation was not present in TF patients. It can be
hypothesized that the combination of peripheral vascular
disease (which was signiﬁcantly more frequent in TA
patients) and severe anaemia might be responsible for the
higher extent of renal damage after TA TAVI.
Access complications are a major drawback of TAVI
procedures, with consequent cases of death in several
studies. In our cohort, we experienced major vascular
complications in 24% of transfemoral procedures. How-
ever, only one death occurred due to vascular damage
(thoracic aortic dissection), indicating that the team was
well prepared to manage these potentially life-threatening
events. Other publications using VARC or comparable
deﬁnitions reported major vascular complications in 16.4
[14] and 16.2% [15] of TF patients, respectively. After the
performance of the ﬁrst 30 cases of overall 59 transfemoral
implantations of Edwards devices in our department, the
introduction of the smaller Novaﬂex catheter as well as
growing experience led to a signiﬁcant decrease of major
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Fig. 3 Event-free survival Kaplan–Meier curves of event-free sur-
vival during follow-up in a all 180 patients treated with TAVI,
b patients after transapical or transfemoral procedures separated, and
c three patient cohorts stratiﬁed according to preoperative logistic
EuroScore mortality estimates
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123vascular complications following these procedures (from
37 to 14%, P = 0.04).
The signiﬁcantly higher rate of new-onset left bundle
branch block and pacemaker implantations after CoreValve
procedures has been consistently documented in many
previous studies and is attributed to the deeper intraven-
tricular insertion of this device. However, the indication for
postprocedural pacemaker implantations was overall rela-
tively low in our patients (5% in the whole cohort, 17% for
CoreValve) compared to other publications reporting rates
between 3.8% (exclusively Edwards prosthesis implanted)
[3] and 39.3% (84% CoreValve devices implanted) [18].
Mid-term survival and morbidity
We reported a 12-month survival of 72% in our cohort,
which compares favourably to data from other series [3, 11,
13, 15, 20] ranging between 69 [15] and 78% [13].
Recently, a 1-year survival of 76.5% was reported for a
great patient cohort (n = 1506) in the SOURCE Registry
[17]. Of note, we observed no difference in 1-year survival
proportions between TA and TF patients (72 vs. 71%,
P = 0.9).
To date, information on further hospitalizations and
incidence of MACCE during follow-up in patients after
TAVI is still limited. In our study, we reported a 1-year
event-free survival of 53% in the whole group which
compares favourably to the ﬁndings of Leon et al. (42.5%
of their patients had reached the composite end point of
death from any cause or repeat hospitalization at 1 year)
[15]. However, event-free-survival in these elderly patients
with signiﬁcant comorbidities is relatively poor. In our
patients, persisting congestive heart failure was the leading
reason for further hospitalization (16%), and a frequent
cause of death during follow-up (3%). Dysfunction of the
prosthetic valve (major paravalvular leak) was present in
two TF patients necessitating reinterventions, but could be
excluded in the majority of cases. In these patients, cardiac
decompensation was attributed either to ischaemic heart
disease, severe mitral regurgitation or severe diastolic
dysfunction due to persisting left ventricular hypertrophy.
In summary, follow-up morbidity seems to be substantially
determined by cardiac comorbidities.
Subgroup analysis of mid-term outcome
We further stratiﬁed all-cause mortality as well as event-
free survival by preoperative logistic EuroScore (with cut-
offs basing on recommended indications for TAVI [4, 5])
creating three subgroups of patients: EuroScore [40%
(n = 28), 20–40% (n = 89), and\20%. In the latter group,
very advanced age ([80 years) represented the principal
reason for the heart team’s preference of TAVI over
conventional surgery (n = 48). To deﬁne a consistent
subgroup, the remaining 15 patients with EuroScore\20%
(including 4 deaths) were not included in the following
analysis because of very heterogeneous comorbidities jus-
tifying their treatment with TAVI. However, their inclusion
would not have changed the statistical result. Figure 2c
demonstrates the survival curves of the three deﬁned sub-
groups which differed signiﬁcantly (P = 0.009). One-year
survival proportions were 62% in patients with a preoper-
ative logistic EuroScore of [40% (observed median
survival of 409 days), 71% in patients with EuroScore
20–40%, and 80% in octogenarians with EuroScore\20%.
Regarding event-free survival as an indicator for morbidity,
we obtained similar even though not statistically signiﬁcant
results (P = 0.1). Patients with a logistic EuroScore[40%
had a 1-year event-free survival of 46%, in contrast to 52%
in the second and 62% in the third group (Fig. 3c).
Observed median event-free survival was 315, 442 and
710 days in the previously deﬁned subgroups.
In conclusion, the stratiﬁcation by preoperative logistic
EuroScore (which is commonly used as a tool to predict
30-day mortality) allowed a convincing 1-year survival
prognosis in our cohort, whereas the stratiﬁcation by
approach did not. Our results are suggesting that mortality
and event-free survival do not primarily depend on the type
of approach, but rather on the incidence of comorbidities.
In Europe, the logistic EuroScore has been widely
accepted by cardiologists and cardiac surgeons as a ‘‘gold
standard’’ [21] to aquire a general idea of peri-operative
risk. In recent years it has become evident that it overes-
timates in-hospital mortality and that its discriminatory
ability in patients undergoing aortic valve surgery is worse
than in patients with isolated coronary surgery [22, 23].
Therefore, Dewey et al. [24] suggested the Society of
Thoracic Surgeons (STS) Score as the most reliable single
risk scoring model for both peri-operative mortality and
long-term survival after isolated AVR in extremely high-
risk patients. However, the STS score is much more
sophisticated than the logistic EuroScore complicating its
routine use in daily clinical practice. Furthermore, Leon-
tyev et al. [25] found that stratiﬁcation of octogenarians
undergoing surgical AVR by logistic EuroScore revealed
no signiﬁcant differences in peri-operative outcomes, but
proved good at differentiating survival during medium-
term follow-up. The utility of both surgical prediction
scores in the context of TAVI is frequently questioned.
However, in our opinion the strength of scoring systems is
to provide some kind of risk stratiﬁcation for different
patient cohorts (regardless of the calculated absolute
value), whereas they are unsuitable for the prediction of an
individual patient’s risk and cannot replace clinical
judgement as the crucial factor of medical decision-
making.
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123But does the performance of TAVI procedures in
otherwise relatively healthy octogenarians fulﬁl the con-
dition of ‘‘off-label-use’’? Other TAVI series included up
to 60% of patients with a logistic EuroScore \20% [18],
and our own cohort compares favourably to the Source
Registry [16] which consists to one-third of such patients.
According to current apprehensions, the rapid spread of the
TAVI technique carries the danger of withdrawing good
surgical candidates from conventional aortic valve
replacement. However, in our opinion this reproach would
not be appropriate concerning our cohort of octogenarians
characterized by a mean age of 84 ± 3 years and a mean
logistic EuroScore of 14 ± 3%. As we learned from the
study of Iung et al. [2], surgery is denied in at least one-
third of elderly patients with symptomatic AS, and
‘‘advanced age’’ represents the main reason for denial of
surgery. Opponents of TAVI could argue that conventional
AVR is feasible in octogenarians. Previously reported in-
hospital mortality rates [26–28] ranged between 4.5 [28]
and 9% [27] in selected octogenarians (logistic EuroScore
not reported). Lately, the results of the PARTNER trial [3]
demonstrated a mortality rate of 6.5% after surgical AVR
in patients randomized for either TAVI or surgery. How-
ever, in our own speciﬁc patient cohort, in-hospital mor-
tality was 2% with just one case of death. In addition, in
this elderly population not only mortality but also mor-
bidity after surgery is an important consideration. Ben-Dor
et al. [29] reported a signiﬁcant reduction of quality of life
in one-ﬁfth of elderly patients after surgical AVR, and
some even lost their independence. Furthermore, prolonged
hospital stays ([14 days) following this intervention were
reported in up to 50% of elderly patients [26]. Finally,
concerns of device durability do not have a high priority in
octogenarians, and Gurvitch et al. [11] already demon-
strated the absence of relevant device deterioration in a
period up to 3 years.
According to our data, octogenarians with logistic
EuroScore \20% seem to be acceptable candidates for
TAVI procedures with good mid-term survival and rea-
sonably low morbidity. In contrast, patients with logistic
EuroScore [40% do poorly and survive on average little
more than 1 year, suggesting that indication for TAVI and
risk-to-beneﬁt ratio should be validated carefully in each
single case.
Conclusions
Procedural safety and outcome data of TAVI in high-risk
patients are convincing, although TAVI unquestionably
remains a highly invasive procedure. The widespread used
logistic EuroScore for the prediction of peri-interventional
mortality rather reﬂects the 1-year mortality in our patients.
Concerning the type of approach, bleeding complications
occurred more frequently in the TF and worsening of renal
function more often in the TA group, but survival and
rehospitalization rates did not differ signiﬁcantly. In our
opinion, neither procedure is per se superior to the other,
but the type of approach should be carefully allocated
according to the patients’ individual comorbidities.
However, mid-term mortality and rate of rehospitaliza-
tion after TAVI are considerably high in speciﬁc patient
cohorts, suggesting that selection criteria for the identiﬁ-
cation of patients who would beneﬁt most from TAVI
procedures need to be reﬁned. In the present study, octo-
genarians with logistic EuroScore \20% could be identi-
ﬁed as candidates with good mid-term survival and
relatively low morbidity.
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